Does Tirzepatide Burn Belly Fat? What the Trial Data Actually Shows

What the SURMOUNT-1 trial found about fat distribution

The landmark SURMOUNT-1 study, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across 72 weeks. Participants at the 15mg dose lost roughly 20–21% of their starting body weight on average, a figure that placed tirzepatide well ahead of anything previously seen in a weight-loss medicine trial. Importantly, the trial included body-composition analysis showing reductions in both subcutaneous fat (the kind you can pinch) and visceral fat.

Visceral fat sits behind the abdominal wall, surrounding the liver, pancreas and intestines. It is metabolically active in ways that raise cardiovascular and metabolic risk, which is precisely why clinicians and researchers pay close attention to it beyond total body weight. The greater the overall weight loss, the more visceral fat tends to fall, and tirzepatide's average losses are large enough that the abdominal changes can be substantial for many people in treatment.

If you want to go deeper on how fat loss plays out in practice on this medicine, our page on tirzepatide and visceral fat covers the body-composition evidence in more detail.

How tirzepatide's dual mechanism targets appetite and fat storage

Most GLP-1 medicines work through a single receptor. Tirzepatide activates two: the GLP-1 receptor and the GIP receptor. GIP is a gut hormone that plays a role in fat cell metabolism as well as insulin secretion, and researchers believe the combined action accounts for the larger average weight reductions seen with tirzepatide compared with GLP-1-only medicines. The NHS medicines page on tirzepatide describes how slowing gastric emptying and reducing appetite work together to lower calorie intake.

When calorie intake consistently falls below what the body burns, it draws on stored energy, including visceral fat. The depth and duration of that deficit matter, which is why tirzepatide's multi-month treatment course is relevant. A single pen won't reshape your midsection; the effect builds across the titration schedule as the dose increases and appetite suppression deepens. Treatment starts at 2.5mg, a dose designed to let your digestive system adjust, and a prescriber moves it up from there based on tolerance and response.

It is worth reading about how Mounjaro (tirzepatide) acts on fat tissue generally for context on the broader mechanism before focusing on the abdominal picture.

Belly fat specifically: what you can and can't control

People often ask whether tirzepatide targets belly fat preferentially, and our guide to Mounjaro and belly fat explores that question in full. What it does is drive enough total loss that even body regions that are often stubborn (the abdomen included) tend to see real change over the course of treatment.

Visceral fat is, in one respect, fortunate: it is more metabolically responsive than subcutaneous fat and tends to reduce relatively early in a weight-loss programme. So even in the first few months of treatment, some people notice their waist measurement moving before the bathroom scales change dramatically. That is a known pattern in significant weight loss, not a tirzepatide-specific superpower.

The practical guide to belly fat loss on Mounjaro covers what you can do alongside treatment (nutrition, protein intake, strength activity) to support the process. The medicine does the heavy lifting on appetite; the lifestyle side shapes where that advantage lands over time.

One small routine detail that some patients find helpful: keeping their pen in the fridge door where they store other weekly essentials keeps injection day visible and consistent, which matters because treatment works through steady, uninterrupted dosing over many months.

Who can access tirzepatide, and what comes next

Tirzepatide (sold as Mounjaro in the UK) is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea or cardiovascular disease. A prescriber assesses your full health profile (not just your BMI) before approving treatment. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NHS access is available but currently follows a phased rollout under NICE technology appraisal TA1026, with strict eligibility criteria that many people don't yet meet. Private treatment through a regulated pharmacy is one route for people who qualify clinically but fall outside the current NHS thresholds or prefer not to wait.

On the cost side, our treatment overview sets out what a private consultation and prescription through nume includes, one transparent price covering clinical review, the prescription, and free next-working-day delivery, with no subscription. If you're comparing options, the Mounjaro overview page is a good starting point before you speak to our prescribers.

Tirzepatide is a prescription-only medicine. If it sounds like it could be right for you, the next step is a clinical consultation. Check your eligibility and start your free consultation with our prescribers.